Clinical Coagulation, Malmö
421 – 430 of 659
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
- Contribution to journal › Article
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
Ekholm, C. ; Mattson, E ; Astermark, Jan LU ; Ljung, Rolf LU
and Berntorp, Erik
LU
(2010)
In Haemophilia
16.
p.90-90
- Contribution to journal › Published meeting abstract
-
Mark
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study
- Contribution to journal › Published meeting abstract
-
Mark
Differential response to bypassing agents
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
(2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
(2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
(2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45
- Contribution to journal › Published meeting abstract
-
Mark
Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients
(2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1504-1504
- Contribution to journal › Published meeting abstract